Short answer
Exelixis Inc (EXEL) filed an 8-K current report with the SEC on September 11, 2026 reporting Item 8.01 (Other Events). FDA review of zanzalintinib plus atezolizumab for metastatic colorectal cancer extended three months.
Exelixis Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA review of zanzalintinib plus atezolizumab for metastatic colorectal cancer extended three months
- Updated PDUFA action date: March 3, 2027
- Extension follows FDA designation of submitted safety and efficacy data as a major amendment
- Regulatory decision delayed, postponing potential U.S. approval and related commercial launch timing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Exelixis Inc 8-K filings
Get the next EXEL 8-K as it lands
Follow EXEL for push alerts, or ask the research agent what this filing means.